Rosiglitazone restores endothelial dysfunction in a rat model of metabolic syndrome through PPAR - And PPAR δ -dependent phosphorylation of Akt and eNOS

PPAR Research

Volumn , Issue , 2011, Pages

  Zhao, Zhigang ^a   Luo, Zhidan ^a   Wang, Peijian ^a   Sun, Jing ^a   Yu, Hao ^a   Cao, Tingbing ^a   Ni, Yinxing ^a   Chen, Jing ^a   Yan, Zhencheng ^a   Liu, Daoyan ^a   Zhu, Zhiming ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ILIAC ARTERY; LIPID DIET; MALE; MESENTERIC ARTERY; METABOLIC SYNDROME X; NONHUMAN; RAT; VASODILATATION;

EID: 84862926291     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2011/291656     Document Type: Article

References (39)

1. Suzuki T., Hirata K., Elkind M. S. V., Jin Z., Rundek T., Miyake Y., Boden-Albala B., Di Tullio M. R., Sacco R., Homma S., Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAS) American Heart Journal 2008 156 2 405 410
2. Tziomalos K., Athyros V. G., Karagiannis A., Mikhailidis D. P., Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management Nutrition, Metabolism and Cardiovascular Diseases 2010 20 2 140 146
3. Wang T. D., Chen W. J., Lin J. W., Chen M. F., Lee Y. T., Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome American Journal of Cardiology 2004 93 3 362 365
4. Esposito K., Ciotola M., Carleo D., Schisano B., Saccomanno F., Sasso F. C., Cozzolino D., Assaloni R., Merante D., Ceriello A., Giugliano D., Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome Diabetes Care 2006 29 5 1071 1076 (Pubitemid 44115246)
5. Mittermayer F., Schaller G., Pleiner J., Krzyzanowska K., Kapiotis S., Roden M., Wolzt M., Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction Journal of Clinical Endocrinology and Metabolism 2007 92 7 2574 2580 (Pubitemid 47037360)
6. Bahia L., Aguiar L. G. K., Villela N., Bottino D., Godoy-Matos A. F., Geloneze B., Tambascia M., Bouskela E., Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome Atherosclerosis 2007 195 1 138 146 (Pubitemid 47566382)
7. Hubacek J., Verma S., Shewchuk L., Ross S. J., Edwards A., Anderson T. J., Rationale and design of the Glitazones and the Endothelium (GATE) study: evaluation of rosiglitazone on endothelial function in patients with diabetes Canadian Journal of Cardiology 2004 20 14 1449 1453 (Pubitemid 40103651)
8. Chan S. H. H., Wu K. L. H., Kung P. S. S., Chan J. Y. H., Oral intake of rosiglitazone promotes a central antihypertensive effect via upregulation of peroxisome proliferator-activated receptor- and alleviation of oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats Hypertension 2010 55 6 1444 1453
9. Sartori-Valinotti J. C., Venegas-Pont M. R., LaMarca B. B., Romero D. G., Yanes L. L., Racusen L. C., Jones A. V., Ryan M. J., Reckelhoff J. F., Rosiglitazone reduces blood pressure in female Dahl salt-sensitive rats Steroids 2010 75 11 794 799
10. Potenza M. A., Marasciulo F. L., Tarquinio M., Quon M. J., Montagnani M., Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance Diabetes 2006 55 12 3594 3603 (Pubitemid 44923622)
11. Albertini J. P., McMorn S. O., Chen H., Mather R. A., Valensi P., Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus Atherosclerosis 2007 195 1 e159 e166
12. Walcher T., Walcher D., Hetzel J., Mielke C., Rau M., Rittig K., Balletshofer B., Schwedhelm E., Hombach V., Bger R. H., Koenig W., Marx N., Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study Diabetes and Vascular Disease Research 2010 7 3 178 185
13. Kleinhenz J. M., Kleinhenz D. J., You S., Ritzenthaler J. D., Hansen J. M., Archer D. R., Sutliff R. L., Hart C. M., Disruption of endothelial peroxisome proliferator-activated receptor- reduces vascular nitric oxide production American Journal of Physiology 2009 297 5 H1647 H1654
14. Sorrentino S. A., Bahlmann F. H., Besler C., Mller M., Schulz S., Kirchhoff N., Doerries C., Horvth T., Limbourg A., Limbourg F., Fliser D., Haller H., Drexler H., Landmesser U., Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor- agonist rosiglitazone Circulation 2007 116 2 163 173 (Pubitemid 47057522)
15. Tian J., Wong W. T., Tian X. Y., Zhang P., Huang Y., Wang N., Rosiglitazone attenuates endothelin-1-induced vasoconstriction by upregulating endothelial expression of endothelin b receptor Hypertension 2010 56 1 129 135
16. Cho D. H., Choi Y. J., Jo S. A., Jo I., Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) -dependent and PPAR -independent signaling pathways Journal of Biological Chemistry 2004 279 4 2499 2506 (Pubitemid 38114233)
17. Wang N., PPAR- in vascular pathophysiology PPAR Research 2008 2008 10
18. Piqueras L., Reynolds A. R., Hodivala-Dilke K. M., Alfranca A., Redondo J. M., Hatae T., Tanabe T., Warner T. D., Bishop-Bailey D., Activation of PPAR / induces endothelial cell proliferation and angiogenesis Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 1 63 69 (Pubitemid 46370477)
19. Jiménez R., Snchez M., Zarzuelo M. J., Romero M., Quintela A. M., Lpez-Seplveda R., Galindo P., Gmez-Guzmn M., Haro J. M., Zarzuelo A., Pérez-Vizcano F., Duarte J., Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor agonists via the phosphatidyl-inositol-3 kinase-Akt pathway Journal of Pharmacology and Experimental Therapeutics 2010 332 2 554 561
20. Ryan M. J., Didion S. P., Mathur S., Faraci F. M., Sigmund C. D., PPAR agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice Hypertension 2004 43 3 661 666 (Pubitemid 38282444)
21. Yan Z. C., Liu D. Y., Zhang L. L., Shen C. Y., Ma Q. L., Cao T. B., Wang L. J., Nie H., Zidek W., Tepel M., Zhu Z. M., Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor- Biochemical and Biophysical Research Communications 2007 354 2 427 433 (Pubitemid 46172454)
22. Yang D., Luo Z., Ma S., Activation of TRPV1 by dietary capsaicin improves endothelium-dependent vasorelaxation and prevents hypertension Cell Metabolism 2010 12 2 130 141
23. He H., Yang D., Ma L., Luo Z., Ma S., Feng X., Cao T., Yan Z., Liu D., Tepel M., Zhu Z., Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor- -dependent pathways Hypertension 2010 55 4 869 879
24. Tziomalos K., Athyros V. G., Karagiannis A., Mikhailidis D. P., Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management Nutrition, Metabolism and Cardiovascular Diseases 2010 20 2 140 146
25. Marchesi C., Ebrahimian T., Angulo O., Paradis P., Schiffrin E. L., Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome Hypertension 2009 54 6 1384 1392
26. Polikandriotis J. A., Mazzella L. J., Rupnow H. L., Hart C. M., Peroxisome proliferator-activated receptor ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor -dependent mechanisms Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 9 1810 1816 (Pubitemid 41243447)
27. Lu X., Guo X., Karathanasis S. K., Zimmerman K. M., Onyia J. E., Peterson R. G., Kassab G. S., Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats Cardiovascular Diabetology 2010 9, article no. 19
28. Hartell N. A., Archer H. E., Bailey C. J., Insulin-stimulated endothelial nitric oxide release is calcium independent and mediated via protein kinase B Biochemical Pharmacology 2005 69 5 781 790 (Pubitemid 40248620)
29. Li R., Zhang H., Wang W., Wang X., Huang Y., Huang C., Gao F., Vascular insulin resistance in prehypertensive rats: role of PI3-kinase/Akt/eNOS signaling European Journal of Pharmacology 2010 628 13 140 147
30. Liang C., Ren Y., Tan H., He Z., Jiang Q., Wu J., Zhen Y., Fan M., Wu Z., Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products British Journal of Pharmacology 2009 158 8 1865 1873
31. Boyle J. G., Logan P. J., Ewart M. A., Reihill J. A., Ritchie S. A., Connell J. M. C., Cleland S. J., Salt I. P., Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase Journal of Biological Chemistry 2008 283 17 11210 11217
32. Luconi M., Cantini G., Serio M., Peroxisome proliferator-activated receptor gamma (PPAR ): is the genomic activity the only answer? Steroids 2010 75 8-9 585 594
33. Welch J. S., Ricote M., Akiyama T. E., Gonzalez F. J., Glass C. K., PPAR and PPAR negatively regulate specific subsets of lipopolysaccharide and IFN- target genes in macrophages Proceedings of the National Academy of Sciences of the United States of America 2003 100 11 6712 6717 (Pubitemid 36666645)
34. Moulin D., Bianchi A., Boyault S., Sebillaud S., Koufany M., Francois M., Netter P., Jouzeau J. Y., Terlain B., Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1 -stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor / -dependent mechanism Arthritis and Rheumatism 2005 52 3 759 769 (Pubitemid 40365097)
35. Mensink M., Hesselink M. K. C., Russell A. P., Schaart G., Sels J. P., Schrauwen P., Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 and PPAR / gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus International Journal of Obesity 2007 31 8 1302 1310 (Pubitemid 47172612)
36. Ali F., Ali N. S., Bauer A., Boyle J. J., Hamdulay S. S., Haskard D. O., Randi A. M., Mason J. C., PPAR and PGC1 act cooperatively to induce haem oxygenase-1 and enhance vascular endothelial cell resistance to stress Cardiovascular Research 2010 85 4 701 710
37. Bishop-Bailey D., Peroxisome proliferator-activated receptors in the cardiovascular system British Journal of Pharmacology 2000 129 5 823 833 (Pubitemid 30142890)
38. Piqueras L., Reynolds A. R., Hodivala-Dilke K. M., Alfranca A., Redondo J. M., Hatae T., Tanabe T., Warner T. D., Bishop-Bailey D., Activation of PPAR / induces endothelial cell proliferation and angiogenesis Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 1 63 69 (Pubitemid 46370477)
39. Hsieh P. S., Hong L. Z., Augmentation of nitric oxide is crucial for the time-dependent effects of rosiglitazone on blood pressure and baroreflex function in rats Journal of Hypertension 2008 26 1 83 92